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PKC-e was isolated from a murine brain eDNA library. The clone, 261PKC-e, encoded apolypeptide of737 amino acids 
that is homologous to other PKCs. Northern analysis howed that the 7 kb mRNA for this eDNA is widely expressed. 
The protein when expressed inCOS-1 cells displayed phorbol ester-binding activity. However in order to detect the kinase 
activity of PKC-e, it was necessary to employ a synthetic peptide substrate based upon the pseudosubstrate si . Subse- 
quent analysis demonstrated that PKC-e, while showing certain properties characteristic of the PKC family, has a quite 
distinct substrate specificity and is independent ofCa 2 +. 
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1. INTRODUCTION 
Prote in  kinase C (PKC),  as first descr ibed by 
Nish izuka and colleagues, has been impl icated in 
the contro l  o f  many cel lular processes (reviewed in 
[1,2]). It is now clear that the general propert ies 
used to def ine the enzyme are shared by a group of  
related proteins first identif ied through structural  
analysis [3-9].  Among these reports,  Housey et al. 
[8] descr ibed a part ial  eDNA clone, RP-16, which 
was only distant ly related to the others. In order to 
def ine the relat ionship o f  this gene product  to the 
PKC family o f  proteins and determine its 
b iochemical  propert ies,  we have isolated a eDNA 
o f  this clone. The sequence o f  this clone is highly 
homologous  to two recently publ ished PKC-e 
eDNA clones [10,11], and is therefore also named 
PKC-e.  By using a synthetic pept ide as a substrate, 
based upon the putat ive pseudosubstrate site o f  
PKC-e,  we have been able to part ia l ly  pur i fy  PKC-  
E. The initial characterist ics o f  this kinase are 
shown to be dif ferent f rom PKC-~,  -B1, -/32, and 
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-Y with respect o Ca 2+ dependence and substrate 
specif icity. 
2. MATERIALS  AND METHODS 
2.1. Isolation of PKC-e from a mouse brain cDNA library 
The synthesis of ollgodeoxyfibonucleotides, theconditions 
for the screening of eDNA libraries and the subsequent analysis 
of positive clones were as described previously [12,13]. 
2.2. Northern blot analysis 
Total RNA was isolated from rat tissues, using the 
guanidinium/cesium chloride method [14]. Total RNA was 
separated on a 1% agarose-formaldehyde gel (20 ,ug/lane) and 
transferred to a nitrocellulose filter. The filter was hyhridised 
with a 32p-labeled random primed PKC-6 eDNA probe (2 x 
109 cpm//~g DNA) in 50070 formamide, 2 x SSC (15 mM 
sodium chloride, 15 mM sodium citrate, pH 7.0), 0.1 070 SDS, 10 
x Denhardt's solution, and 100/~g/ml denatured salmon sperm 
DNA, at 42°C for 20 h [14]. Three moderate 'stringency 
washings were done for 15 min at 50°C in 2 x SSC, 0.1% SDS 
and then one wash for 15 min at 55°C in 0.5 x SSC, 0.1070 SDS. 
The filter was autoradiographed with 2 intensifying screens. 
2.3. Expression in COS-1 cells and anion-exchange 
chromatography 
COS-I cells (5 x 105 cells/10 cm dish) were transfected with 
20/~g of plasmid DNA, using the calcium phosphate precipita- 
tion technique [15]. Cells were harvested after 48 h in 1 ml of 
lysis buffer at 4oC (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 
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1 070 Triton X-100, 0.3070 ~'-mercaptoethanol, 250/zg/ml leupep- 
tin, 50/~g/ml phenylmethylsulphonyl fluoride, and 10 mM ben- 
zamidine) and centrifuged at 13000rpm for 20 min in a 
refrigerated microfuge. Supernatants (1 dish of cells per col- 
umn) were directly applied to a TSK-DEAE-5PW HPLC col- 
umn (LKB, Sweden) at a flow rate of 0.75 ml/min, equilibrated 
in 20mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.3070 /~- 
mercaptoethanol. Proteins were eluted in 0.75 ml fractions with 
a 10 min isocratic wash followed by a linear gradient of NaCI 
in the same buffer (0--0.6 M NaC1 in 40 rain). 
2.4. Kinase assay of PKC-e and phorbol ester binding 
Kinase activity was assayed by using a modified procedure 
[16] of the mixed micelle assay [17]. A sample of each fraction 
(5/zl) was assayed in a total assay volume of 40/zl, containing 
1.25 mg/ml histone III-S (Sigma) or 0.1 mM pep-e. The 
pseudosubstrate site peptide pep-e (see text) was synthesized on 
an Applied Biosystems 430A peptide synthesizer. The phorbol 
12,13-dibutyrate (PDB)-binding assays were carried out as 
previously described [18] except that 20-40/~g/ml 
phosphatidylserine was used. 
2.5. Generation of polyclonal antibodies and immunoblot 
analysis 
A synthetic peptide (NQEEFKGFSYFGEDLMP) based on 
the C-terminal sequence of PKC-E was synthesized, coupled to 
Keyhole limpet hemocyanin (KLH) and used to immunize rab- 
bits as described previously [19]. Protein samples were 
separated on 8070 SDS-polyacrylamide gels, transferred to 
nitrocellulose and blotted [20]. Antiserum was used at a 1/3000 
dilution. 
3. RESULTS AND DISCUSSION 
3.1. cDNA cloning of PKC-• and alignment with 
other PKC members 
An oligodeoxyribonucleotide probe was de- 
signed, based upon the published sequence of a 
partial cDNA clone, RP-16 [8]. The oligodeoxyri- 
bonucleotide, 5 '-CCTTCACGATGACGTTCTC- 
TACCCTGTCTGGCTTAGCAA-3', is contained 
in the C4 region of PKC-• (fig.lb), and was used 
to screen a murine brain eDNA library to obtain 
the complete sequence of this protein. From a 
number of positive plaques, restriction analysis 
showed that four (A61-, A70-, A88-, )t97-PKC-•) 
contained apparently identical full-length coding 
regions and all of these have been shown to encode 
Ca2+-independent phorbol ester-binding proteins 
(not shown). The complete sequence of A61PKC-e 
was obtained according to Sanger et al. [13]. The 
analyses presented below were carried out using 
A61PKC-•, which is referred to in the text as 
APKC-•. 
The predicted amino acid sequence of APKC-e is 
737 amino acids long with a molecular mass of 
83 570 Da. Alignment of this sequence with PKC-• 
from rat and with nPKC from rabbit shows a 99°70 
homology between these three sequences (fig. la). 
11 amino acid changes are present in the V2/V3 
region, which also contains a deletion of Gly-390 
in the rabbit sequence. 8 amino acid changes are 
present in the C4 region. The putative regulatory 
domain of PKC-•, V1/C1, is completely conserved 
between these three species. 
The homology of PKC-E with PKC-a, -/3 and -7 
sequences shows that there is considerable conser- 
vation, with 4807o identity between all four sub- 
types in the kinase domain and 44070 identity 
between all four in the C1 region (within the 
regulatory domain) [4]. However, the homology of 
PKC-• with -a~, -/3 and -7 is clearly lower than those 
between -a, -/? and -7 themselves, which show an 
overall homology of more than 7007o. The major 
areas of divergence with PKC-a, -/31, -/32 and -7 
(as defined in [4]) are the regions V1 and C2 that 
are extended and deleted, respectively (fig.lb). 
Based on the homology to other PKC subtypes and 
from functional considerations, this protein is con- 
sidered to be a member of the PKC superfamily 
and is referred to as PKC-E (see below and [10]). 
3.2. Tissue distribution of PKC-e 
Northern blot analysis of rat tissues with a PKC- 
• probe reveals a single mRNA of 7 kb that is 
abundant in brain and also expressed to some 
degree in all other tissues tudied with heart and 
lung showing quite high levels of expression 
(fig.2). This mRNA species corresponds to that 
identified with an RP16 probe [8] and more recent- 
ly with rat [10] and rabbit [11] PKC-• cDNAs (see 
below). 
3.3. Expression of PKC-e in COS-1 cells, and 
characterisation of the partially purified 
enzyme 
In order to define the properties of the protein 
encoded by APKC-e, the eDNA was subcloned into 
the expression vector pmt-2 (pmt-PKC-e). Tran- 
sient expression i  COS-1 cells led to a 5-fold in- 
crease in cellular phorbol ester binding (not 
shown), as has been observed with the expression 
of other PKC subtypes [5]. This increased binding 
activity was associated with the selective xpression 
of a polypeptide of apparent molecular mass 
89 kDa on SDS-gel electrophoresis (not shown). 
352 
Volume 243, number 2 FEBS LETTERS January 1989 
M MVVFNGLLKIKICEAVSLEPTAWSLREAVGPRPQTFLLDPXIALNVDDSRIGQTATKQKTNSPAWHD~ 70 
Ra 
R~ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
TDVCNGRKI E L A ~  I G~'DDFVANCT I QFEELLQNGSRRFEDWI DLEPE ~ IDLS GS SGEAPK 140 
DNEERVF~ ~VItlt~VHQ~/IIGEEFIgLT YLlt~ T ¥CSUCRD7 IIF~/l GK~YQCQ~ T ~ 210 
RClIE L I I TKCAGLEKQETP DEVG8 ORFSVNMPRXFGI INYKVP TF CDI [CGSLLWGLLRQG~~ 280 
~RCE TNVAPNCGVDARGIAKVLADLGVTPDKITNS~BP QPAS~ 8P 8EDDRSKSAP T S 350 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  IG  . . . . . . .  T - -8  . . . .  • 
PCDQELKELENNIRKALSFDNRGZFJDtASSATDGQLASPGZNGEVI~GOAERLGLDEFNF IKVLGKGSFG 420 
'A - -B  . . . . .  G . . . . . . . .  ~ '  
~LKGEDEVYA~VILQDDDVDCTMTEERI~YLTQLYCCFQTKDRLFFVMEYVN 490 
GGDLMFQ I QRSRKFDEPRSRFYAAEVTSALMFL I IQXGVI  YRDLKLDN I L L D A E G H ~ F ~ G  ~ 560 
G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  8 . . . . . . . . . . . .  L-  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  L -  
GVTT TTFCGTP DY IAPE ILQELEYGP 8 V D ~ Q P  PFEADNEDDLFE8 IT - I rnDVLYP~ 630 
SKEAVS I LKAFMTENP~NGEDAIKQIPFFKE IDRVLLEOXKIKPPFEPR IKTERDVNNFDQ 700 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
DFTREEP ILTLVDEAI IKQINQEEFF~TSYFGEDLMP 737 
. . . . . . . . . . . . . . . .  V . . . . . . . . . . . . . . . . . . . .  
. . . . . . .  V . . . . . . . .  V . . . . . . . . . . . . . . . . . . . .  
REGULATORY CATALYTIC 
I I 
I I I 
vtc- ,.p .y 
cl v2 c2 v~ c~ v 4 c4 vs 
PKC-r[ 
vl cl v2/v~ ca v4 c4 vs 
~N.\N\\\\\\\\\\\\"~ K\\'q N \ \ \ \ \ \ \ \ \ \ \ \ "X \ \ \ "q  I 
Fig. 1. Protein sequence of mouse PKC-e (as predicted from the cDNA sequence), and alignment with PKC-e from rat (Ra) and rabbit 
(Rb). Only divergent amino acids are shown for rat and rabbit. With the exception of a deleted glycine at position 390, no other amino 
acid deletions or insertions are present. Below is shown a schematic diagram of the overall domain structure of PKC-e relative to that 
of PKC-ot,6',-r. This indicates the long extension of PKC-e at the amino-terminus and the deletion of the C2 domain. 
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Fig.2. RNA distribution in rat tissues. A 739 bp XhoI 
fragment, containing 345 nucleotides of a 5'-untranslated 
sequence and 294 nucleotides ofa 5'-translated sequence, was 
used as a PKC-E specific probe which recognized a single 
transcript of 7 kb. The filter was autoradiographed at - 80°C 
for 5 days (top panel) and for 4 weeks (lower panel). Lanes: 1, 
liver; 2, kidney; 3, lung; 4, heart; 5, gut; 6, brain; 7, thymus; 
8, spleen. Although not clear from the reproduction, in the 
original autoradiograph, lanes 1 and 8, like lanes 2, 5 and 7, do 
show a positive signal, albeit somewhat weaker. 
The majority of the induced binding activity was 
found in the cytosolic fraction and was Ca 2+ in- 
dependent, in contrast o the binding activities of 
PKC-te, -~? and -7. However using a conventional 
assay, no significant change in Ca2+/phospho- 
l ipid/TPA-dependent histone (III-S) kinase activi- 
ty was observed in the pmt-PKC-e transfected 
cells. 
In order to investigate further the potential 
kinase activity of PKC-e, use was made of the 
observation by Kemp and colleagues [21] that a 
modified (serine for alanine substitution) 
'pseudosubstrate' site peptide from PKC-a serves 
as a good substrate for purified PKC (probably a 
mixture of subtypes or, fl and 7). In PKC-E there is 
a sequence immediately amino-terminal to the cys- 
teine repeat region that resembles the 
pseudosubstrate sites of other PKC subtypes: this 
sequence (ERMRPRKRQGAVRRRV) was syn- 
thesized (residues 149-164) with the alanine 
(underlined above) replaced by a serine residue 
(referred to as pep-e). 
When pep-e was employed as a substrate to 
screen transfected COS-1 cells, it was apparent 
that PKC-e efficiently phosphorylated this 
substrate (PKC-a could also phosphorylate pep-e 
at a rate equivalent o histone). Fractionation of 
cell extracts howed that multiple peaks of kinase 
activity were obtained following transfection with 
pmt-PKC-e (peaks I - I I I ;  fig.3). Peak I is retarded 
and elutes in the isocratic wash on this column: this 
peak contains some of the PKC-E activity and has 
on occasions been found to co-elute with peak II, 
suggesting that these activities may separate for in- 
cidental reasons, e.g. interaction with other 
cellular components. Peak II represents the ma- 
jority of PKC-e activity but also contains the en- 
dogenous PKC-a activity. Peak I I I  was 
consistently found to elute 8 min after peak II on 
this column: the activity in this peak is 
characteristic of neither PKC-e nor the endogenous 
PKC-a  (see below). 
A polyclonal antibody directed against the C- 
terminus of PKC-E (see section 2.5) was used to 
characterize further the three protein kinase peaks 
obtained from pmt-PKC-e transfected cells. As 
shown in fig.4a, this antiserum specifically 
recognizes a polypeptide of -90  kDa in peaks I 
and II from pmt-PKC-e transfected cells (lanes 2 
and 4) and showed no immunoreactivity with 
equivalent fractions from control transfections 
(lanes 1 and 3). No immunoreactive 90 kDa PKC-E 
was detected in peak II I  (lane 6) although on 
longer exposure (fig.4b) an immunoreactive 
polypeptide of -50  kDa is apparent; it is possible 
that this represents a catalytic fragment of PKC-E 
(see below). 
The properties of the individual peaks obtained 
are summarised in table 1. It is clear from these 
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Fig.3. Separation ofprotein kinase activities by anion exchange 
chromatography. Extracts from COS-I cells transfected with 
the pint-2 vector alone (top panel) or pmt-PKC-e (lower panel) 
were subjected to anion-exchange chromatography on a TSK 
DEAE-5PW column. Fractions were assayed for kinase activity 
with histone (closed symbols) or with pep-~ (open symbols) as 
substrate (see text). 
data  that peaks I and II  d isplay a 
Ca2+-independent phorbol  ester-binding activity 
and a phospho l ip id /phorbo l  ester-dependent pep-e 
kinase activity which is also Ca2+-independent.  
This contrasts trongly with the activities o f  the en- 
dogenous PKC-o~, which shows Ca 2+ dependence 
for both phorbo l  ester binding and kinase activity 
(both pep-e and histone kinase activities). There is 
bare ly  detectable histone kinase activity associated 
with peak I, while that of  peak II  corresponds to 
the endogenous PKC-cr and is character ized by 
Ca 2+ dependence (table 1; see also fig.3 and text). 
This analysis indicates that peak I is PKC-E and 
peak I I  is a mixture o f  the endogenous PKC-o: and 
PKC-e.  The PKC-e kinase activity in peak II is evi- 
dent when one compares the Ca2+-independent 
pep-e kinase activity in the control ,  0.03 U /ml ,  
with the activity in peak I I ,  0.25 U /ml  (table 1). 
In contrast  to peaks I and I I ,  peak I I I  shows 
Fig.4. Identification of PKC-e in transfected COS-I cells. 
Fractions containing the three peaks of pep-e kinase activity 
from pmt-PKC-e transfected cells were immunoblotted using an 
antiserum directed against he C-terminus of the predicted 
PKC-e sequence. The equivalent fractions from a control 
transfection were analysed inparallel. For both panels, lanes 2, 
4 and 6 contain peaks I, II and III, respectively, and lanes 1, 3 
and 5 contain the equivalent fractions from a control 
transfection with pmt-2. The fraction in lane 3 contains the 
endogenous PKC-~ (see top panel of fig.3): this is not 
recognised by the PKC-~ specific antiserum. The markers 
shown are in descending order: 200, 92.5, 69, and 46 kDa. (a) 
A blot exposed for 20 h at room temperature; (b) a longer 
exposure of the same blot (48 h at - 80°C). 
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Table 1 
Characteristics of protein kinase activities in transfected COS-1 cells 
pep-e kinase activity Histone-IIIS kinase activity PDB binding 
Addition: None PS PS/C PS/T PS/T/C None PS PS/C PS/T PS/T/C - C + C 
Control < 1 < 1 < 1 3 15 2 < 1 < 1 8 20 1 4.4 
Peak I < 1 1 1 25 24 < 1 < 1 < 1 < 1 4 24 27 
Peak 11 < 1 < 1 4 25 61 < 1 < 1 < 1 2 35 27 25 
Peak III 29 53 40 51 43 13 13 16 16 13 <0.1 <0.1 
Characteristics of fractionated kinase activities from control and PKC-e expressing COS-I cells. Activities eparated as 
described in the legend to fig.3 were assayed for kinase activities, which are expressed as nmol/min per ml x 102. The 
control activity is the endogenous PKC-ot peak observed in the pmt-2 transfected cells (see upper panel of fig.3). The 
standard kinase assay [18] was carried out with various combinations of PKC effectors present as indicated: PS, 
phosphatidylserine; C, calcium; T, tetradecanoylphorbol acetate; where calcium is omitted, it is replaced by 5 mM 
EGTA. The phorbol 12,13-dibutyrate (PDB)-binding activity was carried out in the presence of 5 mM EGTA ( -  C) 
or in the presence of 0.75 mM total calcium (+ C); units are expressed aspmol PDB bound/ml. All assays are means 
of duplicate determinations. The data shown are from one of several independent experiments 
both pep-e and histone kinase activities and both 
are independent of  the effectors tested (table 1). 
Furthermore this fraction does not bind phorbol 
esters (table 1). It seems likely that this fraction 
contains a catalytic fragment o f  PKC-e that is no 
longer subject to regulation and shows an altered 
specificity. This interpretation would be consistent 
with the immunological data showing the presence 
of  a -50  kDa protein (fig.4b) that may represent a
C-terminal fragment of  PKC-e (the antiserum is 
directed against a C-terminal peptide). However in 
the absence of  further evidence it cannot be ruled 
out that the activity present in peak I I I  is due to an 
unrelated induced or activated protein kinase. 
Further investigation of  substrate specificity has 
shown that none of  the commercially available 
histones (Sigma) nor a-casein will act as substrates 
for PKC-e (peak I or peak II). In contrast, pro- 
tamine and the random copolymers poly-Arg,Ser 
and poly-Lys,Ser will serve as substrates for PKC- 
e, but they are phosphorylated in a 
phosphol ip id/phorbol  ester-independent manner. 
Thus pep-e is the only phosphol ip id/phorbol  ester- 
dependent substrate for PKC-e that has been iden- 
tified to date. 
Recently Ono and colleagues have described the 
cDNA cloning of  PKC-e from a rat eDNA library 
[10]. Furthermore they also show a brief 
characterization of  their expressed rat PKC-E en- 
zyme. However, they detect only one kinase activi- 
ty peak, using histone as a substrate, which would 
appear to correspond to peak I I I  (fig.3). The 
authors conclude from these studies that PKC-E 
shows completely different regulatory features 
compared to other PKC subtypes; this is clearly at 
variance with the data reported here for the murine 
clone. Also recently Ohno et al. [11] reported the 
cDNA cloning of  PKC-e from rabbit. These 
authors also find a PKC-e protein that essentially 
co-elutes with the endogenous PKC-a  on anion- 
exchange chromatography. However it was found 
necessary to immunodeplete he PKC-a  in order to 
detect histone kinase activity associated with the 
expressed PKC-e. As discussed [11], this could 
have been due to the conditions of  the assay or to 
the poor  use of  histone as a substrate. The results 
here resolve this important point by showing that 
it is the specificity of  PKC-e that is different. 
In addition to the apparent Ca z+ independence, 
a unique property of  PKC-e within the context of  
the PKC family is its distinct substrate specificity 
which precludes its ready detection with a histone 
(II I-S) substrate. The use of  the pseudosubstrate 
site as a predictive tool for the generation of  a syn- 
thetic substrate has been important in overcoming 
the problem of  specificity for PKC-e, although it is 
clear f rom the results that this peptide substrate is 
not exclusively phosphorylated by PKC-e, since it 
is also used as a substrate for PKC-a.  Nevertheless 
the use of  pseudosubstrate site peptides may well 
be o f  value in other situations where novel kinases 
are defined through molecular biological ap- 
proaches. 
The implication of  these results is that PKC-e 
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will selectively phosphory late  a part icular  set of  in- 
tracel lu lar  proteins in response to diacylglycerol  
product ion  and that this can occur independent o f  
Ca 2+ release. Thus in the context o f  the 
phosphat idy l inos i to l  pathway,  PKC-e and PKC-a¢ 
(for example) will not s imply funct ion inter- 
changeably,  but will act in paral lel  to target dif- 
ferent sets o f  intracel lular proteins and so diversify 
the cel lular response. Fur thermore  agonist- induced 
degradat ion  o f  other l ipids that produce 
diacylglycerol  independent of  a Ca 2+ mobil is ing 
signal, may selectively lead to the act ivat ion o f  
PKC-E. Thus cellular responses to agonis ts 'cou ld  
be modi f ied  through the expression o f  combina-  
t ions o f  PKC subtypes that differ in their in- 
t racel lu lar  targets and in their Ca 2+ requirement.  
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